Except that these are not immunological markers but genetic markers.
Apart from first and second line ATB presented above, since 2008 extensively drug-resistant (XDR) TB, much more difficult to treat form of MDR TB has been described. By definition, XDR TB is MDR TB with concomitant resistance to any fluoroquinolone and to at least 1 of 3 injectable second-line drugs - amikacin, kanamycin, or capreomycin. So you may want to add other markers such as gyrA, gyrB, rrs, eis, and consider using combinations of them whether assessing the M/XDR TBs.
Immunological markers have been proposed in the past just to assess the response to TB therapy. These markers are surrogate markers : IFNγ-producing ESAT-6 responsive T cells - for blood, and levels of IFNγ, TNF-α, other cytokines - for sputum.
Biomarkers also exist, to determine the serum reactivity (antibodies) specific to MDR TB antigens so to develop a serum diagnosis method based on proteomic analysis. See more on the matter at http://www.proteomesci.com/content/10/1/12